Contact
Please use this form to send email to PR contact of this press release:
Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors
TO:
Please use this form to send email to PR contact of this press release:
Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors
TO: